Eli Lilly and Company

Idun Pharmaceuticals, Inc.

Medivir Ab

Attenuon, LLC

University of Michigan

Histogen, Inc.

American Life Science Pharmaceuticals, Inc.

Nobo Medicine Inc.

Wilson Therapeutics Ab

Robert J Ternansky

John Michael Morin, Jr

Patricia L Gladstone

Kevin J Tomaselli

Rolf Noreen

Donald Karanewsky

Donald S Karanewsky

Andrew P Mazar

Steven D Linton

Peter Tomas Lind

Amy Lynn Allan

David A Hall, Deceased

Charles J Barnett

Louis Nickolaus Jungheim

Richard E Holmes

Sandra K Sigmund

Thang D Dinh

Fernando Donate

Sean M O'Hare

Karen L Valentino

Melissa L P Price

Alfred P Spada

Graham Parry

David A Hall

Stephanie Hopkins

Won Hyung Yoon

Dimitri Coucouvanis

Amy Allan

Rolf Nor&eacute;en

Steven Pirie-Shepherd

Michael Mueller

Peter Thomas Lind

Gregory Hook

Marian Plunkett

Bin Chao

Tomas Lind

Greg Hook

Mellissa L P Price

Sean M O'HARE

Andrew Mazar

Steven Robert Pirie-Shepherd

The present invention relates to (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating e.g. cardiovascular, kidney, liver, lung, skin, joints, CNS, inflammatory and autoimmune diseases.

(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases

In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin. In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g., AD, VD, CDS. The invention also provides alternative dosage forms and formulations for AB-007 and loxistatin, and for compounds of this invention, which can be used e.g., to treat AD, VD and CDS, in humans and in non-human animals.

Compositions and methods for treating beta-amyloid related diseases

The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&#x3ba;B dysregulation.

Thiotungstate analogues and uses thereof

The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&#x3ba;B dysregulation and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&#x3ba;B dysregulation.

Thiomolybdate analogues and uses thereof

This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

This invention is directed to novel sulfonimide (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds having the following structure:wherein A, B, X, R, R, R, n, q, and r are as defined herein. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

Inhibitors of the ICE/ced-3 family of cysteine proteases

The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.

Compounds and methods for inhibition of HIV and related viruses

The instant methods employs pharmaceutical compositions comprising aromatic azines; and imines, of the Formula 1 to selectively inhibit inflammation by preventing the oxidating burst from phagocytic leukocytes caused by NADPH Oxidase.

Method of inhibiting NADPH oxidase

Growing community of inventors

San Diego, CA, United States of America

Robert J Ternansky